Purpose: Inflammation indexes and body mass index (BMI) are easily evaluated, predict survival, and are potentially modifiable. We evaluated the potential association of inflammatory indexes and BMI with the clinical outcome of patients with renal cell carcinoma (RCC) undergoing immune checkpoint inhibitor therapy. Experimental Design: A prospective cohort of patients with metastatic RCC treated with nivolumab enrolled in the Italian Expanded Access Program from July 2015 through April 2016 was examined. Reference measures of inflammation were identified for neutrophil-to-lymphocyte ratio (NLR)

Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab / De Giorgi, U.; Procopio, G.; Giannarelli, D.; Sabbatini, R.; Bearz, A.; Buti, S.; Basso, U.; Mitterer, M.; Ortega, C.; Bidoli, P.; Ferrau, F.; Crino, L.; Frassoldati, A.; Marchetti, P.; Mini, E.; Scoppola, A.; Verusio, C.; Fornarini, G.; Carteni, G.; Caserta, C.; Sternberg, C. N.. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - 25:13(2019), pp. 3839-3846. [10.1158/1078-0432.CCR-18-3661]

Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab

Buti S.;
2019

Abstract

Purpose: Inflammation indexes and body mass index (BMI) are easily evaluated, predict survival, and are potentially modifiable. We evaluated the potential association of inflammatory indexes and BMI with the clinical outcome of patients with renal cell carcinoma (RCC) undergoing immune checkpoint inhibitor therapy. Experimental Design: A prospective cohort of patients with metastatic RCC treated with nivolumab enrolled in the Italian Expanded Access Program from July 2015 through April 2016 was examined. Reference measures of inflammation were identified for neutrophil-to-lymphocyte ratio (NLR)
Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab / De Giorgi, U.; Procopio, G.; Giannarelli, D.; Sabbatini, R.; Bearz, A.; Buti, S.; Basso, U.; Mitterer, M.; Ortega, C.; Bidoli, P.; Ferrau, F.; Crino, L.; Frassoldati, A.; Marchetti, P.; Mini, E.; Scoppola, A.; Verusio, C.; Fornarini, G.; Carteni, G.; Caserta, C.; Sternberg, C. N.. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - 25:13(2019), pp. 3839-3846. [10.1158/1078-0432.CCR-18-3661]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2912886
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 108
  • ???jsp.display-item.citation.isi??? 106
social impact